Inhibitors of ocular neovascularization: promises and potential problems.
van Wijngaarden
Peter
P
Department of Ophthalmology, Flinders University of South Australia, Bedford Park, Adelaide, Australia. vanw0009@flinders.edu.au
Coster
Douglas J
DJ
Williams
Keryn A
KA
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D009841:Oligonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D009841:Oligonucleotides; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000069579:Ranibizumab